These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37827864)

  • 1. IL-2-driven CD8
    Niederlova V; Tsyklauri O; Kovar M; Stepanek O
    Trends Immunol; 2023 Nov; 44(11):890-901. PubMed ID: 37827864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
    Tsyklauri O; Chadimova T; Niederlova V; Kovarova J; Michalik J; Malatova I; Janusova S; Ivashchenko O; Rossez H; Drobek A; Vecerova H; Galati V; Kovar M; Stepanek O
    Elife; 2023 Jan; 12():. PubMed ID: 36705564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
    Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8
    Walker JM; Rolig AS; Charych DH; Hoch U; Kasiewicz MJ; Rose DC; McNamara MJ; Hilgart-Martiszus IF; Redmond WL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T-cell-derived interleukin-15 shapes cytotoxic T cell memory.
    Geginat J; Granucci F
    Eur J Immunol; 2023 Jan; 53(1):e2250238. PubMed ID: 36398486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
    Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
    Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-7/αIL-7 mAb M25 immunocomplexes expand CD8
    Hrabos D; Hnizdilova T; Tomala J; Uhlik J; Kovar M
    Cytokine; 2020 Sep; 133():155174. PubMed ID: 32599539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.
    Sulzmaier FJ; Kern N; Ahn SJ; Polovina A; Ho J; Hussain A; Cyprus G; Macedo C; Pandit R; Crago W; Rowell E; Timmer JC; Eckelman BP
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
    J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.
    Alvarez M; Bouchlaka MN; Sckisel GD; Sungur CM; Chen M; Murphy WJ
    J Immunol; 2014 Aug; 193(4):1709-16. PubMed ID: 25000978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes.
    Stocks BT; Wilson CS; Marshall AF; Hoopes EM; Moore DJ
    J Immunol; 2019 Jul; 203(1):158-166. PubMed ID: 31127035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
    Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
    Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
    Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
    Front Immunol; 2022; 13():974188. PubMed ID: 36059465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.